Abstract
Therapy is often required to manage the hyperglycemia, hypertension, and dyslipidemiathat occur in patients with type 2 diabetes mellitus (T2DM) in order to control the risk ofcardiovascular (CV) events. The importance of managing these risk factors is underscored bythe recommendation from the American Diabetes Association and the American Associationof Clinical Endocrinologists for treatment of these CV risk factors to target levels. However,relatively few patients achieve simultaneous control of these risk factors. As such, therapythat has positive effects on more than 1 risk factor is of potential benefi t. Initially approvedas a lipid-lowering agent, the bile acid sequestrant colesevelam hydrochloride (HCl) is nowalso approved as an adjunct therapy to improve glycemic control in patients with T2DM. Thisreview summarizes the major fi ndings of clinical studies that investigated the glucose- andlipid-lowering effects of colesevelam HCl when added to stable metformin-, sulfonylurea-, orinsulin-based antidiabetes therapies in patients with T2DM.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
